NEO-ANGIN® SUGAR FREE
UkraineThe drug is used for the local treatment of infectious and inflammatory diseases of the mouth, throat, and larynx, such as stomatitis, gingivitis, tonsillitis, pharyngitis, laryngitis, and the early stages of tonsillitis.
Frequently asked questions
How should Neo-angin® sugar free be taken correctly?
Adults and children from 6 years of age should slowly dissolve 1 lozenge every 2–3 hours. The maximum dose is 6 lozenges per day. The course of treatment usually lasts 3–4 days.
What are the possible side effects of Neo-angin® sugar free?
Very rarely, irritation of the oral or gastric mucosa, a burning sensation in the mouth or throat, tingling, tongue pain, as well as nausea, dyspepsia, or stomatitis may occur. Allergic reactions to the coloring agent or isomalt are also possible.
Who should not use this drug?
Use is contraindicated in children under 6 years of age, individuals with hypersensitivity to the components of the composition, as well as patients with fructose intolerance, glucose-galactose malabsorption, or sucrose-isomaltose intolerance.
Can the drug be taken during pregnancy or breastfeeding?
The drug should not be taken during pregnancy or breastfeeding.
What should be done if symptoms do not subside?
If symptoms persist for more than 3 days or are accompanied by high fever and headache, it is necessary to consult a doctor to adjust the treatment.
Instructions for use
INSTRUCTIONS FOR MEDICAL USE OF THE MEDICINAL PRODUCT NEО-ANGIN® SUGAR FREE (NEO-ANGIN® SUGAR FREE)
Composition:
Active substances:
1 lozenge contains 2.4-dichlorobenzyl alcohol 1.2 mg, amylmetacresol 0.6 mg, levomenthol 5.72 mg;
Excipients: star anise oil, peppermint oil, Ponceau 4R dye (E 124), isomalt, tartaric acid.
Pharmaceutical form. Lozenges.
Main physico-chemical characteristics: round, red, slightly biconvex, slightly transparent lozenges with a characteristic odour and pleasant taste.
Pharmacotherapeutic group. Preparations used in throat disorders. Combined antiseptics. ATC code R02A A20.
Pharmacological properties.
Pharmacodynamics.
Neo-Angin® sugar free is active against a broad spectrum of gram-positive and gram-negative microorganisms in vitro; it demonstrates antifungal activity. The efficacy of the preparation is due to the presence of two broad-spectrum antibacterial components, which help relieve sore throat and reduce bacterial effects through a bactericidal action. 2,4-dichlorobenzyl alcohol exerts a bacteriostatic effect by dehydrating the bacterial cell.
Levomenthol complements the action of the other two components of the preparation with an analgesic effect, resulting from stimulation of cold receptors in the mucous membrane.
Pharmacokinetics.
Pharmacokinetic parameters have not been determined.
Clinical characteristics.
Indications. Local treatment (as part of combination therapy) of infectious and inflammatory diseases of the oral cavity, pharynx, and larynx: stomatitis, gingivitis, tonsillitis, early stage of angina, pharyngitis, laryngitis.
Contraindications.
- Hypersensitivity to 2,4-dichlorobenzyl alcohol, amylmetacresol, levomenthol, Ponceau 4R dye, or any other excipient of the medicinal product;
- children under 6 years of age.
Interaction with other medicinal products and other types of interactions.
Unknown.
Special precautions for use.
If symptoms persist for more than 3 days, are accompanied by high fever, headache or other manifestations, consult a physician to adjust the treatment regimen.
The drug should not be used in patients with fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase deficiency.
Use during pregnancy or breastfeeding.
There are no data on the safety of Neo-Angin**®** sugar-free during pregnancy and breastfeeding. Reproductive toxicity studies of this medicinal product in animals have not been conducted. Neo-Angin**®** sugar-free should not be used during pregnancy and breastfeeding.
Ability to influence reaction rate when driving or operating machinery.
Has no effect.
Dosage and Administration
For adults and children aged 6 years and older, sugar-free Neo-Angin® should be slowly dissolved at a rate of one lozenge every 2–3 hours, but not more than 6 lozenges per day. The duration of treatment is
3–4 days.
Children.
Sugar-free Neo-Angin® is contraindicated for children under 6 years of age.
Overdose.
No cases of overdose have been reported.
Side effects.
The following categories are used to assess the frequency of adverse reactions:
Very common (≥ 1/10)
Common (≥ 1/100 to <1/10)
Uncommon (≥ 1/1,000 to <1/100)
Rare (≥ 1/10,000 to <1/1,000)
Very rare (<1/10,000)
Not known (cannot be estimated from the available data)
Immune system disorders.
Not known: hypersensitivity reactions including rash, urticaria, pruritus, anaphylaxis, erythema.
Respiratory, thoracic and mediastinal disorders.
Not known: pharyngeal edema (throat swelling), bronchospasm.
Gastrointestinal disorders.
Very rare: irritation of the oral and gastric mucosa, sensation of discomfort in the mouth (oral burning), throat irritation (throat burning), oral paresthesia (tingling in the mouth), glossodynia (painful tongue).
Very rare: dyspepsia, nausea, stomatitis.
Not known: abdominal pain.
Isomalt and the dye Ponceau 4R (E 124) may cause allergic reactions.
Shelf life. 5 years.
Storage conditions. Store in a dry place at a temperature not exceeding 25 °C. Keep out of reach of children.
Packaging. 2 blisters of 8 lozenges or 2 blisters of 12 lozenges or 4 blisters of 12 lozenges in cardboard boxes.
Classification. Over-the-counter (available without prescription).
Manufacturers.
Divapharma GmbH
Klosterfrau Berlin GmbH
Manufacturer's address and place of business:
Divapharma GmbH:
Motzener Strasse 41, 12277 Berlin, Germany
Klosterfrau Berlin GmbH:
Motzener Strasse 41, 12277 Berlin, Germany
Marketing authorization holder.
Divapharma GmbH
Address of the marketing authorization holder:
Motzener Strasse 41, 12277 Berlin, Germany
Similar drugs
The original data is available in the language of the country of manufacture.
Data source: State Register of Medicinal Products of Ukraine
Data last verified: August 13, 2026